Company: BLND
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001855747-25-000092
Chunk: 368

Company: Blend Labs, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 368
---
 - discontinued operations(182)(20)Net cash provided by investing activities19,79047,284Financing activitiesProceeds from exercises of stock options, including early exercises, net of repurchases1,505869Taxes paid related to net share settlement of equity awards(7,388)(11,003)Share repurchases(9,143)—Repayment of long-term debt—(144,500)Net proceeds from the issuance of the Series A redeemable convertible preferred stock and the Haveli Warrant—149,375Payment for issuance costs related to the Series A redeemable convertible preferred stock and the Haveli Warrant—(9,480)Net cash used in financing activities - continuing operations(15,026)(14,739)Effect of exchange rates on cash, cash equivalents, and restricted cash—(5)Net increase in cash, cash equivalents, and restricted cash15,29624,082Cash, cash equivalents, and restricted cash at beginning of period49,53738,253Cash, cash equivalents, and restricted cash at end of period64,83362,335Less: Cash, cash equivalents and restricted cash included in current assets held for sale from discontinued operations4,7896,742Cash, cash equivalents and restricted cash, end of period, excluding current assets held for sale from discontinued operations$60,044$55,593Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets:Cash and cash equivalents$55,021$50,570Restricted cash5,0235,023Total cash, cash equivalents, and restricted cash$60,044$55,593Supplemental disclosure of cash flow information:Cash paid for income taxes$200$76Cash paid for interest$—$6,150Supplemental disclosure of non-cash investing and financing activities:Reclassification of redeemable noncontrolling interest related to discontinued operations to equity$52,675$—Vesting of early exercised stock options$—$363Operating lease liabilities arising from obtaining new or modified right-of-use assets$1,584$1,151Stock-based compensation included in capitalized internal-use software development costs$2,937$1,941Accretion of redeemable noncontrolling interest related to discontinued operations to redemption value$1,254$4,748Accretion of Series A redeemable convertible preferred stock to redemption value$13,136$6,709Covered Warrant received in connection with strategic partnership and sale of insurance business$—$222Acc